Johnson and Johnson 2015 Annual Report Download - page 18

Download and view the complete annual report

Please find page 18 of the 2015 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 112

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112

Lancaster and Las Piedras manufacturing sites and completed the steps required for third-party certification of the Fort
Washington plant, a third-party cGMP expert submitted written certifications to the FDA for all three manufacturing sites.
Following FDA inspections in 2015, McNEIL-PPC received notifications from the FDA that all three manufacturing facilities
are in conformity with applicable laws and regulations. Commercial production in Fort Washington started as of
September 2015.
Under the Consent Decree, after receiving notice from the FDA of being in compliance with applicable laws and
regulations, each of the three facilities is subject to a five-year audit period by a third-party cGMP expert. Thus, a third-
party expert will continue to reassess the sites at various times for at least five years. A discussion of legal proceedings
related to this matter can be found in Note 21 “Legal Proceedings – Government Proceedings – McNeil Consumer
Healthcare” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
For information regarding lease obligations, see Note 16 “Rental Expense and Lease Commitments” of the Notes to
Consolidated Financial Statements included in Item 8 of this Report. Segment information on additions to property, plant
and equipment is contained in Note 18 “Segments of Business and Geographic Areas” of the Notes to Consolidated
Financial Statements included in Item 8 of this Report.
Item 3. Legal Proceedings
The information called for by this item is incorporated herein by reference to the information set forth in Note 21 “Legal
Proceedings” of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
In addition, Johnson & Johnson and its subsidiaries are from time to time party to government investigations, inspections or
other proceedings relating to environmental matters, including their compliance with applicable environmental laws.
Item 4. Mine Safety Disclosures
Not applicable.
Executive Officers of the Registrant
Listed below are the executive officers of the Company as of February 23, 2016. There are no family relationships
between any of the executive officers, and there is no arrangement or understanding between any executive officer and
any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors,
the executive officers are elected by the Board to hold office for one year and until their respective successors are elected
and qualified, or until earlier resignation or removal.
Information with regard to the Directors of the Company, including information for Alex Gorsky, is incorporated herein by
reference to the material captioned “Item 1: Election of Directors” in the Proxy Statement.
Name Age Position
Dominic J. Caruso
58
Member, Executive Committee; Vice President, Finance; Chief Financial
Officer(a)
Peter M. Fasolo 53 Member, Executive Committee; Vice President, Global Human Resources(b)
Alex Gorsky
55
Chairman, Board of Directors; Chairman, Executive Committee; Chief Executive
Officer
Sandra E. Peterson 57 Member, Executive Committee; Group Worldwide Chairman(c)
Paulus Stoffels
54
Member, Executive Committee; Chief Scientific Officer; Worldwide Chairman,
Pharmaceuticals(d)
Michael H. Ullmann 57 Member, Executive Committee; Vice President, General Counsel(e)
(a) Mr. D. J. Caruso joined the Company in 1999 when the Company acquired Centocor, Inc. At the time of that acquisition, he had been
Senior Vice President, Finance of Centocor. Mr. Caruso was named Vice President, Finance of Ortho-McNeil Pharmaceutical, Inc., a
subsidiary of the Company, in 2001 and Vice President, Group Finance of the Company’s Medical Devices and Diagnostics Group in
2003. In 2005, Mr. Caruso was named Vice President of the Company’s Group Finance organization. Mr. Caruso became a Member
of the Executive Committee and Vice President, Finance and Chief Financial Officer in 2007.
6•Johnson & Johnson 2015 Annual Report